title: BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.|Department of Hematology, University hospital, Nantes, France.|INSERM UMR892, CNRS UMR6299, University of Nantes, Nantes, France.
authors.forename: C
authors.initials: C
authors.lastname: Touzeau
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: J
authors.initials: J
authors.lastname: Ryan
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: J
authors.initials: J
authors.lastname: Guerriero
authors.affiliation: Department of Hematology, University hospital, Nantes, France.|INSERM UMR892, CNRS UMR6299, University of Nantes, Nantes, France.
authors.forename: P
authors.initials: P
authors.lastname: Moreau
authors.affiliation: Conway Institute of Biomolecular and Biomedical Research, Dublin, Ireland.
authors.forename: T N
authors.initials: TN
authors.lastname: Chonghaile
authors.affiliation: Department of Hematology, University hospital, Nantes, France.|INSERM UMR892, CNRS UMR6299, University of Nantes, Nantes, France.
authors.forename: S
authors.initials: S
authors.lastname: Le Gouill
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: P
authors.initials: P
authors.lastname: Richardson
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: K
authors.initials: K
authors.lastname: Anderson
authors.affiliation: INSERM UMR892, CNRS UMR6299, University of Nantes, Nantes, France.
authors.forename: M
authors.initials: M
authors.lastname: Amiot
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: A
authors.initials: A
authors.lastname: Letai
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000814:Aniline Compounds / Q000138:chemical synthesis / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000494:pharmacology*; D001681:Biological Assay; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000138:chemical synthesis / Q000494:pharmacology; D045744:Cell Line, Tumor; D045304:Cytochromes c / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D064549:Myeloid Cell Leukemia Sequence 1 Protein / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D009928:Organ Specificity; D010455:Peptides / Q000138:chemical synthesis / Q000494:pharmacology*; D010950:Plasma Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D012008:Recurrence; D013449:Sulfonamides / Q000138:chemical synthesis / Q000494:pharmacology; D051020:bcl-X Protein / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
chemical_list: D000814:Aniline Compounds; D000970:Antineoplastic Agents; C000595707:BCL2 protein, human; C494811:BCL2L1 protein, human; D019086:Bridged Bicyclo Compounds, Heterocyclic; C579095:MCL1 protein, human; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D010455:Peptides; D019253:Proto-Oncogene Proteins c-bcl-2; D013449:Sulfonamides; D051020:bcl-X Protein; D045304:Cytochromes c; C579720:venetoclax; C528561:navitoclax